SciSparc Advances Cannabinoid-Based Therapies for CNS Disorders, Including Autism

Key Insights

• SciSparc has enrolled the first patient in its clinical trial for SCI-210, a cannabinoid-based treatment for Autism Spectrum Disorder (ASD) in children.
• The company's pipeline includes SCI-110 for Tourette Syndrome and Alzheimer's agitation, and SCI-160 for pain management, all leveraging cannabinoid pharmaceuticals.
• SciSparc has expanded its intellectual property portfolio with recent patents in the U.S., Canada, and Europe, enhancing its competitive position.

SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company, is making strides in developing cannabinoid-based therapies for central nervous system (CNS) disorders. The company's diverse pipeline targets conditions such as Tourette Syndrome, Alzheimer's disease, pain, Autism Spectrum Disorder (ASD), and status epilepticus, utilizing both THC and non-psychoactive CBD.

SCI-210 Clinical Trial for Autism Spectrum Disorder

A significant milestone for SciSparc is the enrollment of the first patient in its clinical trial for SCI-210, a proprietary treatment combining cannabidiol (CBD) and CannAmide™ for children with ASD. This trial marks a crucial step in addressing the unmet medical needs of individuals with ASD, a condition affecting a significant portion of the pediatric population.

Expanding Therapeutic Pipeline

Beyond SCI-210, SciSparc's pipeline includes SCI-110, aimed at treating Tourette Syndrome and Alzheimer's agitation, and SCI-160 for pain management. These programs underscore the company's commitment to leveraging the therapeutic potential of cannabinoids to address a range of CNS disorders.

Intellectual Property and Partnerships

SciSparc is actively expanding its intellectual property portfolio, with recent patents granted in the U.S., Canada, and Europe. These patents cover innovative compositions that enhance the therapeutic effects of cannabinoids while reducing side effects. The company's commitment to scientific excellence is further highlighted by its collaborations and partnerships, including its venture with MitoCareX Bio, which leverages advanced computational platforms for cancer drug discovery, targeting mitochondrial SLC25 proteins.

Online Sales and Market Presence

In addition to its pharmaceutical development efforts, SciSparc owns a subsidiary focused on online sales of hemp-based wellness products, including gummies, oils, capsules, and creams, available on platforms like Amazon Marketplace. This diversified approach allows SciSparc to maintain a market presence while advancing its clinical programs.